Skip to main content
NCBI home page
Netherlands Heart Journal logoLink to Netherlands Heart Journal
. 2006 Feb;14(2):55-58, 59-61.

Primary angioplasty: preprocedural pharmacological therapy

N Ernst, M-J de Boer, F Zijlstra, H Suryapranata, J-HE Dambrink, JCA Hoorntje, AWJ van 't Hof
PMCID: PMC2557156  PMID: 25696594

Abstract

Primary coronary angioplasty has been shown to be an effective reperfusion therapy for patients with acute myocardial infarction, not only for those who present to PTCA centres but also for patients who present to hospitals without angioplasty facilities. With the increasing use of primary angioplasty more patients will be transferred to a (tertiary) PTCA centre. An increase in treatment delay is associated with a worse clinical outcome. The importance of an open infarct-related vessel at acute angiography is becoming clear. Pharmacological pretreatment of patients during transportation to a PTCA centre with the aim to open the infarct-related vessel in advance might be beneficial. Glycoprotein IIb/IIIa receptor blockers seem to be the agents of choice for facilitated PTCA. The safety and (cost) effectiveness of this pretreatment of patients transported to undergo primary angioplasty remain to be evaluated.

Keywords: PTCA, transportation, myocardial infarction

Full text

PDF
55

Images in this article

56Figure 1
on p.56

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antman E. M., Giugliano R. P., Gibson C. M., McCabe C. H., Coussement P., Kleiman N. S., Vahanian A., Adgey A. A., Menown I., Rupprecht H. J. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation. 1999 Jun 1;99(21):2720–2732. doi: 10.1161/01.cir.99.21.2720. [DOI] [PubMed] [Google Scholar]
  2. Antman Elliott M., Anbe Daniel T., Armstrong Paul Wayne, Bates Eric R., Green Lee A., Hand Mary, Hochman Judith S., Krumholz Harlan M., Kushner Frederick G., Lamas Gervasio A. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004 Aug 4;44(3):671–719. doi: 10.1016/j.jacc.2004.07.002. [DOI] [PubMed] [Google Scholar]
  3. Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001 Aug 25;358(9282):605–613. doi: 10.1016/S0140-6736(01)05775-0. [DOI] [PubMed] [Google Scholar]
  4. Brener S. J., Barr L. A., Burchenal J. E., Katz S., George B. S., Jones A. A., Cohen E. D., Gainey P. C., White H. J., Cheek H. B. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998 Aug 25;98(8):734–741. doi: 10.1161/01.cir.98.8.734. [DOI] [PubMed] [Google Scholar]
  5. Cannon C. P., Gibson C. M., Lambrew C. T., Shoultz D. A., Levy D., French W. J., Gore J. M., Weaver W. D., Rogers W. J., Tiefenbrunn A. J. Relationship of symptom-onset-to-balloon time and door-to-balloon time with mortality in patients undergoing angioplasty for acute myocardial infarction. JAMA. 2000 Jun 14;283(22):2941–2947. doi: 10.1001/jama.283.22.2941. [DOI] [PubMed] [Google Scholar]
  6. Cutlip D. E., Cove C. J., Irons D., Kalaria V., Le M., Cronmiller H., Caufield L., Pomerantz R. M., Ling F. S. Emergency room administration of eptifibatide before primary angioplasty for ST elevation acute myocardial infarction and its effect on baseline coronary flow and procedure outcomes. Am J Cardiol. 2001 Jul 1;88(1):A6, 62-4. doi: 10.1016/s0002-9149(01)01587-9. [DOI] [PubMed] [Google Scholar]
  7. Dalby M., Bouzamondo A., Lechat P., Montalescot G. Transfer for primary angioplasty versus immediate thrombolysis in acute myocardial infarction: a meta-analysis. Circulation. 2003 Oct 6;108(15):1809–1814. doi: 10.1161/01.CIR.0000091088.63921.8C. [DOI] [PubMed] [Google Scholar]
  8. De Luca Giuseppe, Ernst Nicolette, Zijlstra Felix, van 't Hof Arnoud W. J., Hoorntje Jan C. A., Dambrink Jan-Henk E., Gosslink A. T. Marcel, de Boer Menko-Jan, Suryapranata Harry. Preprocedural TIMI flow and mortality in patients with acute myocardial infarction treated by primary angioplasty. J Am Coll Cardiol. 2004 Apr 21;43(8):1363–1367. doi: 10.1016/j.jacc.2003.11.042. [DOI] [PubMed] [Google Scholar]
  9. De Luca Giuseppe, Suryapranata Harry, Ottervanger Jan Paul, Antman Elliott M. Time delay to treatment and mortality in primary angioplasty for acute myocardial infarction: every minute of delay counts. Circulation. 2004 Mar 8;109(10):1223–1225. doi: 10.1161/01.CIR.0000121424.76486.20. [DOI] [PubMed] [Google Scholar]
  10. Di Mario Carlo, Bolognese Leonardo, Maillard Luc, Dudek Dariusz, Gambarati Giampaolo, Manari Antonio, Guiducci Vincenzo, Patrizi Giampiero, Rusconi Luigi Cesare, Piovaccari Giancarlo. Combined Abciximab REteplase Stent Study in acute myocardial infarction (CARESS in AMI). Am Heart J. 2004 Sep;148(3):378–385. doi: 10.1016/j.ahj.2004.03.038. [DOI] [PubMed] [Google Scholar]
  11. Dudek Dariusz, Zmudka Krzysztof, Kaluza Grzegorz L., Kuta Marcin, Pieniazek Piotr, Przewlocki Tadeusz, Zorkun Cafer, Legutko Jacek, Gajos Grzegorz, Bartuś Stanislaw. Facilitated percutaneous coronary intervention in patients with acute myocardial infarction transferred from remote hospitals. Am J Cardiol. 2003 Jan 15;91(2):227–229. doi: 10.1016/s0002-9149(02)03112-0. [DOI] [PubMed] [Google Scholar]
  12. Gibson C. M., de Lemos J. A., Murphy S. A., Marble S. J., McCabe C. H., Cannon C. P., Antman E. M., Braunwald E., TIMI Study Group Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation. 2001 May 29;103(21):2550–2554. doi: 10.1161/01.cir.103.21.2550. [DOI] [PubMed] [Google Scholar]
  13. Gold H. K., Garabedian H. D., Dinsmore R. E., Guerrero L. J., Cigarroa J. E., Palacios I. F., Leinbach R. C. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation. 1997 Apr 1;95(7):1755–1759. doi: 10.1161/01.cir.95.7.1755. [DOI] [PubMed] [Google Scholar]
  14. Grines C. L., Browne K. F., Marco J., Rothbaum D., Stone G. W., O'Keefe J., Overlie P., Donohue B., Chelliah N., Timmis G. C. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1993 Mar 11;328(10):673–679. doi: 10.1056/NEJM199303113281001. [DOI] [PubMed] [Google Scholar]
  15. Kastrati Adnan, Mehilli Julinda, Schlotterbeck Klaus, Dotzer Franz, Dirschinger Josef, Schmitt Claus, Nekolla Stephan G., Seyfarth Melchior, Martinoff Stefan, Markwardt Christina. Early administration of reteplase plus abciximab vs abciximab alone in patients with acute myocardial infarction referred for percutaneous coronary intervention: a randomized controlled trial. JAMA. 2004 Feb 25;291(8):947–954. doi: 10.1001/jama.291.8.947. [DOI] [PubMed] [Google Scholar]
  16. Liem A. L., van 't Hof A. W., Hoorntje J. C., de Boer M. J., Suryapranata H., Zijlstra F. Influence of treatment delay on infarct size and clinical outcome in patients with acute myocardial infarction treated with primary angioplasty. J Am Coll Cardiol. 1998 Sep;32(3):629–633. doi: 10.1016/s0735-1097(98)00280-0. [DOI] [PubMed] [Google Scholar]
  17. Liem A., Zijlstra F., Ottervanger J. P., Hoorntje J. C., Suryapranata H., de Boer M. J., Verheugt F. W. High dose heparin as pretreatment for primary angioplasty in acute myocardial infarction: the Heparin in Early Patency (HEAP) randomized trial. J Am Coll Cardiol. 2000 Mar 1;35(3):600–604. doi: 10.1016/s0735-1097(99)00597-5. [DOI] [PubMed] [Google Scholar]
  18. Montalescot G., Barragan P., Wittenberg O., Ecollan P., Elhadad S., Villain P., Boulenc J. M., Morice M. C., Maillard L., Pansiéri M. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001 Jun 21;344(25):1895–1903. doi: 10.1056/NEJM200106213442503. [DOI] [PubMed] [Google Scholar]
  19. Montalescot Gilles, Borentain Maria, Payot Laurent, Collet Jean Philippe, Thomas Daniel. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis. JAMA. 2004 Jul 21;292(3):362–366. doi: 10.1001/jama.292.3.362. [DOI] [PubMed] [Google Scholar]
  20. Ross A. M., Coyne K. S., Reiner J. S., Greenhouse S. W., Fink C., Frey A., Moreyra E., Traboulsi M., Racine N., Riba A. L. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J Am Coll Cardiol. 1999 Dec;34(7):1954–1962. doi: 10.1016/s0735-1097(99)00444-1. [DOI] [PubMed] [Google Scholar]
  21. Savonitto S., Armstrong P. W., Lincoff A. M., Jia G., Sila C. A., Booth J., Terrosu P., Cavallini C., White H. D., Ardissino D. Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J. 2003 Oct;24(20):1807–1814. doi: 10.1016/j.ehj.2003.07.004. [DOI] [PubMed] [Google Scholar]
  22. Stone G. W., Cox D., Garcia E., Brodie B. R., Morice M. C., Griffin J., Mattos L., Lansky A. J., O'Neill W. W., Grines C. L. Normal flow (TIMI-3) before mechanical reperfusion therapy is an independent determinant of survival in acute myocardial infarction: analysis from the primary angioplasty in myocardial infarction trials. Circulation. 2001 Aug 7;104(6):636–641. doi: 10.1161/hc3101.093701. [DOI] [PubMed] [Google Scholar]
  23. Stone Gregg W., Grines Cindy L., Cox David A., Garcia Eulogio, Tcheng James E., Griffin John J., Guagliumi Giulio, Stuckey Thomas, Turco Mark, Carroll John D. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002 Mar 28;346(13):957–966. doi: 10.1056/NEJMoa013404. [DOI] [PubMed] [Google Scholar]
  24. Topol E. J., GUSTO V Investigators Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001 Jun 16;357(9272):1905–1914. doi: 10.1016/s0140-6736(00)05059-5. [DOI] [PubMed] [Google Scholar]
  25. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation. 2000 Jun 20;101(24):2788–2794. doi: 10.1161/01.cir.101.24.2788. [DOI] [PubMed] [Google Scholar]
  26. Van de Werf Frans, Ardissino Diego, Betriu Amadeo, Cokkinos Dennis V., Falk Erling, Fox Keith A. A., Julian Desmond, Lengyel Maria, Neumann Franz-Josef, Ruzyllo Witold. Management of acute myocardial infarction in patients presenting with ST-segment elevation. The Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology. Eur Heart J. 2003 Jan;24(1):28–66. doi: 10.1016/s0195-668x(02)00618-8. [DOI] [PubMed] [Google Scholar]
  27. Verheugt F. W., Liem A., Zijlstra F., Marsh R. C., Veen G., Bronzwaer J. G. High dose bolus heparin as initial therapy before primary angioplasty for acute myocardial infarction: results of the Heparin in Early Patency (HEAP) pilot study. J Am Coll Cardiol. 1998 Feb;31(2):289–293. doi: 10.1016/s0735-1097(97)00495-6. [DOI] [PubMed] [Google Scholar]
  28. Vermeer F., Oude Ophuis A. J., vd Berg E. J., Brunninkhuis L. G., Werter C. J., Boehmer A. G., Lousberg A. H., Dassen W. R., Bär F. W. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart. 1999 Oct;82(4):426–431. doi: 10.1136/hrt.82.4.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Zijlstra F., Hoorntje J. C., de Boer M. J., Reiffers S., Miedema K., Ottervanger J. P., van 't Hof A. W., Suryapranata H. Long-term benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999 Nov 4;341(19):1413–1419. doi: 10.1056/NEJM199911043411901. [DOI] [PubMed] [Google Scholar]
  30. Zijlstra F., de Boer M. J., Hoorntje J. C., Reiffers S., Reiber J. H., Suryapranata H. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial infarction. N Engl J Med. 1993 Mar 11;328(10):680–684. doi: 10.1056/NEJM199303113281002. [DOI] [PubMed] [Google Scholar]
  31. Zijlstra F., van 't Hof A. W., Liem A. L., Hoorntje J. C., Suryapranata H., de Boer M. J. Transferring patients for primary angioplasty: a retrospective analysis of 104 selected high risk patients with acute myocardial infarction. Heart. 1997 Oct;78(4):333–336. doi: 10.1136/hrt.78.4.333. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Zijlstra Felix, Ernst Nicolette, de Boer Menko-Jan, Nibbering Edwin, Suryapranata Harry, Hoorntje Jan C. A., Dambrink Jan-Henk E., van 't Hof Arnoud W. J., Verheugt Freek W. A. Influence of prehospital administration of aspirin and heparin on initial patency of the infarct-related artery in patients with acute ST elevation myocardial infarction. J Am Coll Cardiol. 2002 Jun 5;39(11):1733–1737. doi: 10.1016/s0735-1097(02)01856-9. [DOI] [PubMed] [Google Scholar]
  33. de Lemos J. A., Antman E. M., Gibson C. M., McCabe C. H., Giugliano R. P., Murphy S. A., Coulter S. A., Anderson K., Scherer J., Frey M. J. Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial. Circulation. 2000 Jan 25;101(3):239–243. doi: 10.1161/01.cir.101.3.239. [DOI] [PubMed] [Google Scholar]
  34. van den Merkhof L. F., Zijlstra F., Olsson H., Grip L., Veen G., Bär F. W., van den Brand M. J., Simoons M. L., Verheugt F. W. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study. J Am Coll Cardiol. 1999 May;33(6):1528–1532. doi: 10.1016/s0735-1097(99)00038-8. [DOI] [PubMed] [Google Scholar]

Articles from Netherlands Heart Journal are provided here courtesy of Springer

RESOURCES